Cargando…

Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy

BACKGROUND: The prognostic utility of systemic inflammatory markers has so far not been investigated in patients with metastatic testicular germ cell tumours (GCTs). METHODS: International Germ Cell Cancer Cooperative Group (IGCCCG) risk groups and blood-based systemic inflammatory markers (haemoglo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fankhauser, Christian Daniel, Sander, Sophia, Roth, Lisa, Gross, Oliver, Eberli, Daniel, Sulser, Tullio, Seifert, Burkhardt, Beyer, Joerg, Hermanns, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877429/ https://www.ncbi.nlm.nih.gov/pubmed/29485982 http://dx.doi.org/10.1038/bjc.2017.467

Ejemplares similares

Frequent PD-L1 expression in testicular germ cell tumors
por: Fankhauser, C D, et al.
Publicado: (2015)

CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors
por: Fankhauser, Christian Daniel, et al.
Publicado: (2019)

Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer
por: Nitzsche, B, et al.
Publicado: (2012)

Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours
por: Mendoza, J, et al.
Publicado: (2013)

Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells
por: Fung, M K L, et al.
Publicado: (2006)

Risk factors and treatment outcomes of 239 patients with testicular granulosa cell tumors: a systematic review of published case series data
por: Grogg, Josias Bastian, et al.
Publicado: (2020)

GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours
por: Shamash, J, et al.
Publicado: (2007)

The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro
por: Alain, T, et al.
Publicado: (2006)

Oncological and functional outcomes after testis-sparing surgery in patients with germ cell tumors: a systematic review of 285 cases
por: Grogg, Josias Bastian, et al.
Publicado: (2022)

Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth
por: Patel, J B, et al.
Publicado: (2007)

Retroperitoneal teratoma with somatic malignant transformation: A papillary renal cell carcinoma in a testicular germ cell tumour metastasis following platinum-based chemotherapy
por: Zeh, Nina, et al.
Publicado: (2013)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response
por: Ivarsson, K, et al.
Publicado: (2005)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro
por: Koch, S, et al.
Publicado: (2003)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
por: Palumbo, A, et al.
Publicado: (2011)

Intra-tumoural extra-cellular pH: a useful parameter of response to chemotherapy in syngeneic tumour lines
por: Lindner, D, et al.
Publicado: (2009)

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
por: Piccirillo, S G M, et al.
Publicado: (2012)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model
por: Girard, E, et al.
Publicado: (2012)

The role of superoxide anions in the development of distant tumour recurrence
por: ten Kate, M, et al.
Publicado: (2006)

Using macrophage activation to augment immunotherapy of established tumours
por: Fridlender, Z G, et al.
Publicado: (2013)

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy
por: Tazzari, M, et al.
Publicado: (2014)

Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy
por: Lammers, T, et al.
Publicado: (2008)

Macrophages promote angiogenesis in human breast tumour spheroids in vivo
por: Bingle, L, et al.
Publicado: (2006)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

The endothelin B (ET(B)) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification
por: Cemazar, M, et al.
Publicado: (2005)

Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI
por: Gambarota, G, et al.
Publicado: (2008)

Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy
por: Dudek, A Z, et al.
Publicado: (2007)

Photodynamic therapy-generated vaccines: relevance of tumour cell death expression
por: Korbelik, M, et al.
Publicado: (2007)

PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer
por: Su, Y, et al.
Publicado: (2010)

False-negative MRI biomarkers of tumour response to targeted cancer therapeutics
por: Boult, J K R, et al.
Publicado: (2012)

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
por: Veltman, J D, et al.
Publicado: (2010)

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
por: Pires, I M, et al.
Publicado: (2012)

Oxidative stress specifically downregulates survivin to promote breast tumour formation
por: Pervin, S, et al.
Publicado: (2013)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomas
por: Separovic, D, et al.
Publicado: (2009)

Immunisation with ‘naïve’ syngeneic dendritic cells protects mice from tumour challenge
por: Grimshaw, M J, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_nhkgh2oj8f3g6b4plrspq9po1b